Genmab

	11/12 11:38 af GeorgeBest	@Bulder. Jan will probably say it is a Janssen product, and refer the analyst to them.
	11/12 11:37 af ProInvestorNEWS	(link)
	11/12 11:28 af Bulder	(link) talquetamab
	11/12 11:17 af Bulder	Seems like a little concern over the fatal infections in the tec-dara-len combo. One covid and one sepsis. Hope this will be discussed on R&D Day.
	11/12 10:35 af E L	PET scan for Richters / epco (link)
	11/12 09:59 af E L	Ash 2022 – talquetamab heads to the regulators (link)
	11/12 09:55 af E L	It's a while ago this was written 'Assuming epco gets approved, and 1 biontech duobody, then for these first 9 Genmab approved antibodies, 8 of them will be blockbusters, Kesimpta will be multiple blockbuster, Teclistamab, Talquetamab, Tepezza now are prognosed for >$4bn and Dara and Rybrevant >$5bn. That is just unheard of for a biotech.' but seems fully on track... maybe Mim8 will be #9 though, as GB suggested or even Inclacumab...
	11/12 09:33 af E L	Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma (link)
	11/12 09:30 af E L	Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) in Combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma (link)
	11/12 08:37 af ProInvestorNEWS	Jim Omel @IMFjimMYELOMA More Than 70% of Heavily Pretreated Patients Taking Talquetamab for Multiple Myeloma See Responses That “Deepen Over Time” (link) via @AJMC_Journal More exciting immunotherapy news from ASH. 70% response to a new myeloma cell surface target. (link)
	11/12 08:31 af Stroka	Det ser godt ud for talquetamab og teclistamab.
	11/12 08:28 af Stroka	God morgen :-)
	11/12 08:11 af ProInvestorNEWS	MyelomaTeacher - Cindy Chmielewski @MyelomaTeacher Hope - for RRMM (link)
	11/12 08:05 af ProInvestorNEWS	Ben Derman @bdermanmd · 11 t Rub some ‘DRT’ on it. MajesTEC-2 with Dara/Len/Tec. ORR 93.5% in a less refractory population with high rates of CR (55%). No data on mrd negativity among the CR population. But definitely makes a case for combination strategies for teclistamab(link)
	11/12 08:00 af ProInvestorNEWS	oseph Mikhael @jmikhaelmd master presenter Ajai Chari presenting Talquetamab a bispecific antibody targeting GPRC5D. Amazing 74% ORR and even more remarkable low infection rates grade 3/4 at 17% and 12%. This is remarkable and may likely be the next bispecific and First GPRC5D available (link)
	11/12 07:58 af ProInvestorNEWS	Raj Chakraborty @rajshekharucms · 11 t Although I am super excited about teclistamab combinations in earlier lines of therapy, 6.25% fatal AEs 2/2 infection in Dara-Tec-Len is concerning. Need to develop new strategies to mitigate infection risk such that greater efficacy is not neutralized by high tox (link)
	11/12 07:54 af ProInvestorNEWS	'New lease on life' for blood cancer patients as experimental therapy treats 73 PERCENT of patients in global clinical trials The treatment targets recurring multiple myeloma, a type of blood cancer More than 30 percent of trial patients saw all traces of their cancer disappear Talquetamab work as well or better than similar multiple myeloma treatments (link)
	11/12 06:52 af Helge Larsen/PI-redaktør	Godmorgen. :-)
	11/12 01:17 af GeorgeBest	Exciting responses to bispecific epcoritamab for Richter's transformed CLL, which can be very tricky to treat (link)
	10/12 13:30 af gentogen	Nu vi er ved det, så er efterbehandlngen af Lu AF82422 in Participants With Multiple System Atrophy (AMULET) netop blevet forlænget. Ikke at man kan lægge ret meget i det, men måske alligevel et lille positivt tegn???
	10/12 10:30 af E L	on BMS-986253 (link) (link)
	10/12 09:37 af Helge Larsen/PI-redaktør	Positive Early Results of Mim8 Pave Way for Testing in Phase 3 Trials (link)
	10/12 09:30 af Helge Larsen/PI-redaktør	Enig GB. Det er vildt og imponerende.
	10/12 08:41 af GeorgeBest	Ret vildt at tænke på at når Epco og Talquetamab bliver godkendte i løbet af næste år, vil der være 8 Genmab udviklede produkter på markedet. Hvad mon bliver nr. 9. Mim8 fra Novo??

	10/12 08:29 af GeorgeBest	Volume på Genmab ADS var vist ekstraordinær høj i går - næsten 1.4 mill. omsat
	10/12 07:41 af ProInvestorNEWS	Godmorgen :-) Opdateret status oversigt for det Danske OMX C25 Index fra NordStock fredag d. 9. december - købs- og salgsignaler: (link)
	10/12 01:05 af gentogen	(link)
	10/12 01:04 af gentogen	The anti-interleukin (IL)-8 monoclonal antibody, BMS-986253 combined with nivolumab showed preliminary activity in melanoma progressing on checkpoint inhibitors, as reported in a phase I/II trial presented at ESMO Immuno-Oncology Congress 2022
	9/12 17:49 af gdn55	Derfor er jeg langsigtet, har haft Genmab siden kurs 35,60.
	9/12 17:48 af gdn55	Men stiger fra 1875 til godt 3300 fra først i junni
	9/12 17:39 af Vitus	Sådan tænker jeg ikke, når Genmab falder fra over kurs 3000 til under kurs 2000…
	9/12 17:16 af Vitus	Ja, så er det godt man har APM og Vestas ….
	9/12 16:20 af nohope	Man skulle tro det var Novo der havde indsendt en BLA.
	9/12 16:07 af Sukkeralf	Thats really nice
	9/12 15:41 af E L	just a year after teclistamab; that was dec21 (and approved oct22)
	9/12 15:38 af E L	Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (link)
	9/12 15:04 af JKY_VH	:-D Bulder
	9/12 15:03 af GeorgeBest	5 years looks okay for. Can I get the same return the next 5 years, I’ll be happy :-)
	9/12 14:55 af nohope	You are probably right, we have to go back 10 years to make it look great.I can´t do 10 years, but this 5 years compared to Novo, which steadily pays annual dividend.(link)
	9/12 14:47 af StockBull	Im ok with the moon
	9/12 14:37 af Bulder	The sky above nohope is always black.
	9/12 14:35 af GeorgeBest	Well, the sky has been quite blue the last 10 years. Why would you make it grey then?
	9/12 14:18 af nohope	The problem with Mygind is that according to him then is the sky over Genmab is not just always blue, it is luminiscent.
	9/12 13:44 af Bulder	Nsclc er en svær øvelse (link)
	9/12 12:37 af E L	"Genmab: Præsenterede torsdag data for Gen1042 der var bedre end forventet" (link) -I still can't find anything about it; we'll probably have to wait for the R&D day
	9/12 12:36 af E L	Genmab rider på en bølge af succes David Mygind Fredag 09. december (link)
	9/12 07:49 af GeorgeBest	#ASH22 Talquetamab, a GPRC5D x CD3 Bispecific Antibody, in Patients with RRMM. At 0.4 mg/kg/week: ORR 73%, median PFS 7.5 months. (link)
	9/12 07:24 af Stroka	God morgen :-)
	9/12 07:18 af Helge Larsen/PI-redaktør	Godmorgen :-)
	9/12 03:29 af Doublo	God morgen fra Tyrkiet klart du må starte før kl. 5 Helge, eller kunne du slet ikke nå det du når.